P. Schein

P. Schein, R. Davis, N. Rakieten, 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

The use of nicotinamide to modify the toxicity of streptozotocin diabetes without loss of antitumor activity.

P. Schein, D. Cooney, M. L. Vernon, 1967, Cancer research.

Effects of streptozotocin on carbohydrate and lipid metabolism in the rat.

K. Alberti, P. Schein, D. Williamson, 1971, Endocrinology.

Management of gastrointestinal cancer.

P. Schein, J. Heal, Joanna M. Heal, 1977, The Medical clinics of North America.

Streptozotocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature.

V. Devita, P. Schein, R. Kahn, 1973, Archives of internal medicine.

Phase I studies on chlorozotocin

P. Woolley, P. Schein, J. Macdonald, 1978, Clinical pharmacology and therapeutics.

Clinical pharmacology of daunorubicin in phase I patients with solid tumors: development of an analytical methodology for daunorubicin and its metabolites.

P. Schein, F. Smith, A. Rahman, 1984, Seminars in oncology.

Maintenance chemotherapy for advanced Hodgkin's disease in remission.

V. Devita, P. Schein, B. Chabner, 1973, Lancet.

Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.

P. Schein, C. Blanke, M. Kurman, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ovarian carcinoma metastatic to the diaphragm--frequently undiagnosed at laparotomy. A preliminary report.

V. Devita, P. Schein, B. Chabner, 1973, American journal of obstetrics and gynecology.

Recent results of clinical therapeutic trials for gastrointestinal malignancies conducted in the United States.

P. Schein, J. Macdonald, D. Kisner, 1981, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Nephrotoxicity of cis-diamminedichloroplatinum(II) as measured by urinary beta-glucuronidase.

J. K. Moriarty, P. Schein, J. Kuhn, 1980, Cancer treatment reports.

Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry.

P. Woolley, P. Schein, L. Chiazze, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5‐fluorouracil, adriamycin, and mitomycin‐c (fam) combination chemotherapy in the treatment of advanced gastric cancer

P. Woolley, P. Schein, D. Hoth, 1979, Cancer.

Prediction of clinical response to 5-fluorouracil-containing chemotherapy: preliminary results of in vitro assay in human breast cancer.

P. Schein, M. Lippman, J. Macdonald, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Comparative pharmacology of pentamethylmelamine and hexamethylmelamine in mice.

A. Goldin, P. Schein, M. Morimoto, 1980, Cancer research.

179 Promotion of multilineage hematopoiesis in patients with myelodysplastic syndrome: A phase I/II clinical trial with amifostine

P. Schein, A. List, B. Glinsmann-Gibson, 1997 .

Percutaneous liver biopsy, peritoneoscopy and laparotomy: an assessment of relative merits in the lymphomata.

V. Devita, P. Schein, B. Chabner, 1975, The British journal of cancer. Supplement.

Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.

C. Gisselbrecht, P. Woolley, P. Schein, 1986, Cancer treatment reports.

Current management of advanced and locally unresectable gastric carcinoma.

P. Woolley, P. Schein, F. Smith, 1982, Cancer.

Hexamethylmelamine as a single second‐line agent in ovarian cancer

P. Schein, A. Manetta, E. Podczaski, 1990, Gynecologic oncology.

1-methyl-1-nitrosourea and dialkylnitrosamine depression of nicotinamide adenine dinucleotide.

P. Schein, 1969, Cancer research.

Streptozotocin : Depression of Mouse Liver Pyridine Nucleotides ' PhilipS

P. Schein, S. Loftus, 2022 .

Cellular and Molecular Mechanisms of the Bone Marrow Sparing Effects of the Glucose

P. Schein, T. MacVittie, L. Erickson, 2005 .

Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy

P. Woolley, P. Schein, J. Macdonald, 1988, Investigational New Drugs.

Cutaneous seeding of pancreatic cancer by skinny-needle aspiration biopsy.

P. Schein, J. Macdonald, R. Ornitz, 1980, Archives of internal medicine.

Phase-II trial of tamoxifen in advanced breast cancer

P. Woolley, P. Schein, D. Hoth, 2004, Cancer Chemotherapy and Pharmacology.

Phase-II trial of tamoxifen in advanced breat cancer.

P. Woolley, P. Schein, D. Hoth, 1979, Cancer chemotherapy and pharmacology.

A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil.

P. Woolley, P. Schein, F. Smith, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapeutic management of the hormone‐secreting endocrine malignancies

P. Schein, 1972, Cancer.

Organic thiophosphate WR-151327 suppresses expression of HIV in chronically infected cells.

P. Schein, T. Kalebic, 1994, AIDS research and human retroviruses.

Carcinoid carcinomatous meningitis.

P. Schein, M. Linnoila, R. Nagourney, 1985, Annals of internal medicine.

Modification of Renal Tumorigenic Effect of Streptozotocin by Nicotinamide: Spontaneous Reversibility of Streptozotocin Diabetes 1

P. Schein, N. Rakieten, D. Cooney, 1976, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Chemotherapy of large intestinal carcinoma. Current results and future prospects

P. Schein, J. Macdonald, D. Kisner, 1975, Cancer.

Esophageal carcinoma following irradiation for breast cancer

P. Schein, R. Curtis, T. Goffman, 1983, Cancer.

Renal tumorigenic action of streptozotocin (NSC-85998) in rats.

P. Schein, R. Davis, N. Rakieten, 1968, Cancer chemotherapy reports.

Cutaneous T‐cell lymphoma

P. Schein, J. Macdonald, R. Edelson, 1976, Cancer.

Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu)

V. Devita, P. Schein, B. Chabner, 1973 .

Peritoneoscopy: a valuable staging tool in ovarian carcinoma.

V. Devita, P. Schein, B. Chabner, 1975, Annals of internal medicine.

A comparison of the biological and biochemical properties of 1-(4-amino-2-methylpyrimidin-5-yl)methyl-3-(2-chloroethyl)-3-nitrosourea and 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose.

P. Schein, R. Nagourney, P. Fox, 1978, Cancer research.

Preclinical toxicology of anticancer agents.

P. Schein, 1977, Cancer research.

Treatment of malignant melanoma with methyl CCNU

V. Devita, H. Brereton, P. Schein, 1974, Clinical pharmacology and therapeutics.

SEPTEMBER 1973 3-( Tetraacetyl Glucopyranos-2-yl )-1-( 2-chloroethyl ) 4-nitrosourea , an Antitumor Agent with Modified Bone Marrow Toxicity

P. Schein, T. Anderson, M. McMenamin, 2022 .

Antitumor Activity and Bone Marrow Toxicity of Aminoglucose Mustard Anticancer Agents in Mice 1

P. Schein, J. Cantrell, D. Green, 2006 .

6-[Bis(2-chloroethyl)amino]-6-deoxygalactopyranose hydrochloride (C6-galactose mustard), a new alkylating agent with reduced bone marrow toxicity.

P. Schein, S. Dean, D. Green, 1987, Cancer research.

Repair of DNA alkylation induced in L1210 leukemia and murine bone marrow by three chloroethylnitrosoureas.

K. Tew, P. Schein, D. Green, 1982, Cancer research.

Chlorozotocin. Mechanism of reduced bone marrow toxicity in mice.

P. Schein, L. Panasci, D. Green, 1979, The Journal of clinical investigation.

Sensitivity of human and murine hematopoietic precursor cells to 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose and 1,3-bis(2-chloroethyl)-1-nitrosourea.

P. Schein, D. Hoth, J. Bull, 1978, Cancer research.

Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response.

P. Schein, B. Ardalan, M. Buscaglia, 1978, Biochemical pharmacology.

A phenol technique for extraction of alkylated DNA, RNA, and protein from a single tissue sample.

D. C. Green, P. Schein, L. Panasci, 1977, Analytical biochemistry.

Streptozotocin Diabetes in Monkeys and Dogs, and Its Prevention by Nicotinamide

P. Schein, R. Davis, N. Rakieten, 1973, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Biological and biochemical properties of the 2-hydroxyl metabolites of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.

P. Schein, J. Heal, P. Fox, 1978, Cancer research.

Renal cell carcinoma causing a selective mineralocorticoid insufficiency.

R. Mariani-Costantini, P. Schein, G. Schechter, 1982, The Journal of urology.

Treatment of cancer-associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion.

R. Goldberg, P. Woolley, P. Schein, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma

P. Schein, J. Berenberg, K. Ryan, 1981, Cancer.

Current diagnosis and management of pancreatic carcinoma.

P. Schein, J. Macdonald, L. Widerlite, 1976, Journal of the National Cancer Institute.

Sorbent removal of adriamycin in vitro and in vivo.

J. Winchester, P. Schein, L. Mortensen, 1979, Cancer treatment reports.

The role of chemotherapy in the management of gastric and pancreatic carcinomas.

P. Schein, 1985, Seminars in oncology.

Fractionation of mammalian bone marrow by counterflow centrifugation‐elutriation using a continuous albumin gradient: analysis of granulocyte‐macrophage colony‐forming units

P. Schein, T. MacVittie, P. Byrne, 1982, British journal of haematology.

Mitomycin C: Experience in the United States, with emphasis on gastric cancer

P. Schein, J. Macdonald, D. Hoth, 2004, Cancer Chemotherapy and Pharmacology.

Clinical strategies in the chemotherapy of gastrointestinal cancer.

P. Woolley, P. Schein, J. Macdonald, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

A phase II trial of ftorafur. Adriamycin and mitomycin‐C (FAM II) in advanced gastric adenocarcinoma

P. Woolley, D. Haller, P. Schein, 1979, Cancer.

Mitomycin C: experience in the United States, with emphasis on gastric cancer.

P. Schein, D. Hoth, J. Macdonald, 1978, Cancer chemotherapy and pharmacology.

500 Amifostine (AMI) selectively protects against cumulative toxicities of cyclophosphamide (C) and cisplatin (P)

P. Schein, W. Oster, D. Belpomme, 1995 .

577 Amifostine reduces cumulative cisplatin nephrotoxicity

P. Schein, W. Oster, R. Capizzi, 1995 .

Elevated topoisomerase II activity and altered chromatin in nitrogen mustard-resistant human cells.

R. Hertzberg, P. Schein, M. Mattern, 1987, NCI monographs : a publication of the National Cancer Institute.

A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.

D. Amadori, R. Coombes, P. Schein, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Synthesis and Murzne P388 Antitumor Activity of Uridine Mustard: A Preliminary Report

P. Schein, D. Green, A. Talebian, 1990 .

Chemotherapeutic Alteration of Small Intestinal Morphology and Function: A Progress Report

P. Schein, F. Smith, D. Kisner, 1979, Journal of clinical gastroenterology.

Prognostic factors in Burkitt's lymphoma importance of total tumor burden

R. Simon, P. Schein, I. Magrath, 1980, Cancer.

Laetrile toxicity: a report of two cases.

P. Schein, S. Cohan, F. Smith, 1977, JAMA.

Binding of chlorozotocin and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea to chromatin and nucleosomal fractions of HeLa cells.

K. Tew, P. Schein, M. Smulson, 1978, Cancer research.

Aspartato(1,2-cyclohexanediamine)platinum(II) complexes : synthesis and characterization; effects of minor impurities on antitumor activity

P. Schein, C. Hammer, D. Green, 1991 .

Gastrointestinal toxicity of chemotherapeutic agents.

P. Schein, E. Mitchell, Edith P. Mitchell, 2006, Seminars in oncology.

Lupus vulgaris and Hodgkin's disease.

H. R. Vickers, P. Schein, 1972, Archives of dermatology.

Gastrointestinal involvement in the Sézary syndrome.

P. Schein, M. Cohen, A. Fischmann, 1977, Gastroenterology.

Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma.

V. Devita, P. Schein, B. Chabner, 1976, Annals of internal medicine.

Immunosuppressive and cytotoxic chemotherapy: long-term complications.

P. Schein, S. Winokur, Winokur Sh, 1975, Annals of internal medicine.

DNA Alkylation Damage in L1210 cells Effect of Carbamoylation on the Repair of Nitrosourea-induced

P. Schein, J. Heal, P. Fox, 2013 .

Effect of carbamoylation on the repair of nitrosourea-induced DNA alkylation damage in L1210 cells.

P. Schein, J. Heal, P. Fox, 1979, Cancer research.

Phase I clinical trial of spirogermanium.

P. Woolley, P. Schein, M. Slavik, 1980, Cancer treatment reports.

Biological and biochemical properties of 1-(2-chloroethyl)-3-(beta-D-glucopyranosyl)-1-nitrosourea (NSC D 254157), a nitrosourea with reduced bone marrow toxicity.

P. Schein, L. Panasci, P. Fox, 1977, Cancer research.

A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice.

P. Schein, L. Panasci, R. Nagourney, 1977, Cancer research.

CEA (carcinoembryonic antigen): Its role as a marker in the management of cancer

K. Isselbacher, P. Schein, V. Go, 2004, Journal of Cancer Research and Clinical Oncology.

Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo.

P. Schein, R. Young, D. Goldberg, 1973, Biochemical pharmacology.

Antitumor and toxicity evaluation of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes

P. Schein, Aquilur Rahman, A. Casazza, 2004, Cancer Chemotherapy and Pharmacology.

The potential for clinical application of in vitro assays predicting 5-FU sensitivity in man.

P. Schein, M. Lippman, J. Macdonald, 1981, Cancer treatment reports.

Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation.

P S Schein, V. Ferrans, P. Schein, 1983, Cancer research.

Amifostine‐mediated protection of normal bone marrow from cytotoxic chemotherapy

P S Schein, P. Schein, R L Capizzi, 1993, Cancer.

New sugar mitomycin C analogues: preparation, murine P388 antitumor activity, and leukopenia induction.

P. Schein, C. Hammer, D. Green, 1990, Journal of pharmaceutical sciences.

Correlation of nitrosourea murine bone marrow toxicity with deoxyribonucleic acid alkylation and chromatin binding sites.

K. Tew, P. Schein, T. Hisamatsu, 1982, Biochemical pharmacology.

Influence of hydrocortisone on the binding of nitrosoureas to nuclear chromatin subfractions.

K. Tew, P. Schein, M. Smulson, 1980, Cancer research.

Pharmacological, toxicological, and therapeutic evaluation in mice of doxorubicin entrapped in cardiolipin liposomes.

P. Schein, A. Rahman, N. More, 1985, Cancer research.

Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity.

P. Schein, A. Rahman, A. Goodman, 1984, Seminars in oncology.

Antitumor and pharmacologic disposition studies of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Abstr.

A. Goldin, P. Schein, Aquilur Rahman, 1983 .

Toxicity evaluation of doxorubicin entrapped in cardiolipin liposomes in mice. Abstr.

P. Schein, I. Kline, Aquilur Rahman, 1983 .

A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma

P. Schein, Philip S. Schein, 1982, Cancer.

A phase I study of daunorubicin in advanced untreatable malignancies.

P. Schein, J. Harvey, A. Goodman, 1984, Seminars in oncology.

Chemotherapy of the blastic phase of chronic granulocytic leukemia: hypodiploidy and response to therapy.

J. Whang‐Peng, V. Devita, P. Schein, 1976, Blood.

Chemotherapy of Non-Hodgkin's Lymphoma Potential for Prolonged Disease-free Survival Following Combination

P. Schein, B. Chabner, C. Berard, 2011 .

Results of combination chemotherapy of non-Hodgkin's lymphoma.

V. Devita, P. Schein, B. Chabner, 1975, The British journal of cancer. Supplement.

Non‐Hodgkin's lymphoma: Patterns of relapse from complete remission after combination chemotherapy

P S Schein, R C Young, V. Devita, 1975, Cancer.

Letter: Meningeal involvement in lymphoma.

P. Bunn, P. Schein, 1974, The New England journal of medicine.

Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma.

V. Devita, P. Schein, B. Chabner, 1974, Blood.

The Toxicity of Escherichia coli L-Asparaginase1

P. Schein, Ruth D. Davis, N. Rakieten, 2006 .

The toxicity of Escherichia coli L-asparaginase.

D. Rall, P. Schein, R. Davis, 1969, Cancer research.

Differentiation of carcinomatous and bacterial meningitis

P. Schein, A. Deisseroth, J. Morganroth, 1972, Neurology.

Prednimustine: the rationale for clinical development.

F. Cavalli, P. Schein, 1986, Seminars in oncology.

Biology, diagnosis, and chemotherapeutic management of pancreatic malignancy.

P. Schein, J. Macdonald, L. Widerlite, 1977, Advances in pharmacology and chemotherapy.

Receptor-Mediated Endocytosis by Normal and Proliferating Hepatocytes and Liposomal Drug Delivery

P. Schein, A. Wolkoff, R. Stockert, 1984 .

Phase II trial of spirogermanium in breast adenocarcinoma: a Cancer and Leukemia Group B Study.

W. Wood, P. Schein, D. Budman, 1982, Cancer treatment reports.

Chemotherapy of advanced ovarian carcinoma: a prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamide.

V. Devita, P. Schein, B. Chabner, 1974, Gynecologic oncology.

DNA repeat length in chromatin from murine bone marrow and L1210 leukaemia cells.

K. Tew, P. Schein, A. E. Clark, 1985, British Journal of Cancer.

Phase II study of sequential methotrexate-5-FU therapy in advanced measurable colorectal cancer.

P. Schein, F. Smith, C. Lagarde, 1982, Cancer treatment reports.

The case for a new national program for the development of cancer therapeutics.

P. Schein, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Panel: cancer of the pancreas.

B. Levin, P. Schein, W. Remine, 1978, American journal of surgery.

Combination chemotherapy for advanced breast cancer: response and effect on survival.

V. Devita, P. Schein, B. Chabner, 1976, Annals of internal medicine.

Minimal activity of recombinant clone a interferon in metastatic colon cancer.

P. Schein, J. Neefe, M. Ayoob, 1984, Journal of Biological Response Modifiers.

Phase-II study of cis-diammine-dichloro platinum (cis-platinum), bleomycin and methotrexate for advanced squamous cell carcinoma of head and neck

P. Woolley, P. Schein, W. Ueno, 2004, Cancer Chemotherapy and Pharmacology.

Therapy of advanced lymphocytic lymphoma a preliminary report of a randomized trial between combination chemotherapy (CVP) and intensive radiotherapy.

V. Devita, P. Schein, B. Chabner, 1975, The British journal of cancer. Supplement.

Chemotherapy of pancreatic carcinoma

P. Schein, F. Smith, S. Zimmerman, 1981, Cancer.

Phase I trial and clinical pharmacology of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea.

P. Woolley, P. Schein, S. Korsmeyer, 1981, Cancer research.

Gastric carcinoma and thrombotic thrombocytopenic purpura: association with plasma immune complex concentrations.

R. Coffey, P. Schein, T. Phillips, 1982, British medical journal.

Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin‐d in advanced measurable pancreatic carcinoma. A gastrointestinal tumor study group report

R J Reitemeier, P S Schein, J. Barkin, 1978, Cancer.

Structure-activity studies of methylnitrosourea antitumor agents with reduced murine bone marrow toxicity.

P. Schein, L. Panasci, P. Fox, 1977, Cancer research.

The role of hexamethylmelamine in the management of ovarian cancer.

P. Schein, W. McCulloch, B. Scheffler, 1991, Cancer treatment reviews.

Unique sensitivity of nitrogen mustard-resistant human Burkitt lymphoma cells to novobiocin.

P. Schein, M. Mattern, R. Boyce, 1988, Biochemical pharmacology.

Biochemical and pharmacologic properties of nitrosoureas.

K. Tew, P. Schein, A. Wang, 1981, Cancer treatment reports.

Use of amifostine in bone marrow purging.

E. Shpall, P. Schein, M. Ross, 1996, Seminars in oncology.

5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU.

P. Woolley, P. Schein, J. Macdonald, 1976, Cancer treatment reports.

6-bis-(2-chloroethyl)amino-6-deoxy-D-galactopyranose hydrochloride: synthesis, chemical characterization, murine P388 antitumor activity, and bone marrow toxicity.

P. Schein, C. Hammer, D. Green, 1989, Journal of pharmaceutical sciences.

Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma.

P. Schein, T. le Chevalier, F. Smith, 1985, Seminars in oncology.

Studies on mechanisms of 5-fluorouracil resistance in murine and human tumors.

P. Schein, J. Macdonald, D. Cooney, 1979, Bulletin du cancer.

Hepatotoxicity of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. (CCNU) in dogs: the use of serial percutaneous liver biopsies.

M. Henry, P. Schein, R. Davis, 1973, Toxicology and applied pharmacology.

A phase II study of chlorozotocin in metastatic malignant melanoma

P. Woolley, P. Schein, F. Smith, 1980, Cancer.

1-Methyl-1-nitrosourea Depression of Brain Nicotinamide Adenine Dinucleotide in the Production of Neurologic Toxicity

P. Schein, 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Contributions of nitrosoureas to cancer treatment.

P. Schein, E. Mitchell, 1986, Cancer treatment reports.

7 – CLINICAL PRESENTATIONS OF GASTROINTESTINAL CANCER

P. Schein, 1981 .

Liposomal protection of adriamycin-induced cardiotoxicity in mice.

B. Sikic, P. Woolley, P. Schein, 1980, Cancer research.

Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).

P. Schein, A. Manetta, E. Podczaski, 1991, Cancer treatment reviews.

Estramustine: historical background and preclinical trials.

P. Schein, 1983, Seminars in oncology.

A Phase I trial of spirogermanium administered on a continuous infusion schedule

P. Woolley, P. Schein, V. Priego, 2004, Investigational New Drugs.

Enhancement of nitrosourea cytotoxicity in vitro using hydrocortisone.

K. Tew, P. Schein, D. Lindner, 1982, Biochemical pharmacology.

Phase II study of chlorozotocin in leukemia and other hematologic malignancies.

P. Woolley, P. Schein, D. Hoth, 1981, Cancer treatment reports.

Correlation of nitrosourea bone marrow toxicity with dna alkylation and chromatin binding sites. Abstr.

K. Tew, P. Schein, T. Hisamatsu, 1980 .

Cellular and molecular mechanisms of the bone marrow sparing effects of the glucose chloroethylnitrosourea chlorozotocin.

K. Tew, P. Schein, T. MacVittie, 1984, Blood.

Phase II trial of mitoxantrone in advanced colorectal cancer.

P. Woolley, P. Schein, E. Mitchell, 1982, Cancer treatment reports.

5‐fluorouracil, adriamycin, and mitomycin‐C (FAM) chemotherapy for adenocarcinoma of the lung

P. Woolley, P. Schein, J. Macdonald, 1979, Cancer.

Will hemoperfusion be useful for cancer chemotherapeutic drug removal?

J. Winchester, P. Schein, L. Mortensen, 1980, Clinical toxicology.

CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lung.

P. Woolley, P. Schein, D. Hoth, 1981, Cancer treatment reports.

Mutagenic activity of nitrosourea antitumor agents.

P. Schein, M. Oeschger, B. R. Franza, 1980, Journal of the National Cancer Institute.

Biological and Biochemical Properties of the 2-Hydroxyl Metabolites of 1-( 2-Chloroethy l )-3-cyclohexy 1-1-nitrosourea 1

M. Heal, P. Schein, Patrícia, 2006 .

DNA repeatlength inchromatin frommurine bonemarrow andL1210leukaemia cells

P. Schein, A. E. Clark, S. Dean, 1985 .

Chemotherapy for advanced gastric carcinoma.

D. Haller, P. Schein, 1986, JAMA.

Therapy of Advanced Gastric Carcinoma: The Georgetown‐Lombardi Cancer Center Experience

P. Woolley, P. Schein, J. Macdonald, 1989, American Journal of Clinical Oncology.

Cisplatin in patients with gastric cancer: a Cancer and Leukemia Group B phase II study.

P. Schein, R. Mick, M. Green, 1986, Cancer treatment reports.

Study of nitrosourea glycosyl analogs--V. An oriented phase II trial of RFCNU.

P. Schein, J. Misset, C. Jasmin, 1982, European journal of cancer & clinical oncology.

Preclinical evaluation of WR-151327: an orally active chemotherapy protector.

P. Schein, D. Green, D. Bensely, 1994, Cancer research.

Phase II study of PCNU in colorectal carcinoma.

P. Woolley, P. Schein, E. Mitchell, 1981, Cancer treatment reports.

Barriers to Efficient Development of Cancer Therapeutics

P. Schein, B. Scheffler, 2006, Clinical Cancer Research.

Chemoprotective Effects of Amifostine on Hematopoietic and Nonhematopoietic Tissue

P. Schein, W. Oster, R. Capizzi, 1995 .

Synthesis and Characterization of a Series of Water Soluble Amidomalonato-(lR,2R-Cyclohexanediamine)Platinum(II) Complexes

P. Schein, D. Green, A. Talebian, 1990 .

Murine anti-tumor activity of new water soluble platinum(II) complexes with reduced toxicity.

P. Schein, D. Green, A. Talebian, 1990, Anti-Cancer Drug Design.

Treatment of advanced breast cancer with two doxorubicin‐containing regimens

P. Schein, M. A. Harris, F. Smith, 1984, American journal of clinical oncology.

Pharmacology of chlorozotocin Nsc-178248), a new nitrosourea antitumor agent.

P. Woolley, P. Schein, L. Panasci, 1976, Cancer treatment reports.

COMPUTERISED AXIAL TOMOGRAPHY FOR DIAGNOSIS OF PANCREATIC CANCER

D. Schellinger, P. Schein, J. Harbert, 1976, The Lancet.

A phase II trial of high‐dose intravenous interferon alpha‐2 in advanced colorectal cancer

P. Schein, S. Rudnick, J. Rothman, 1984, Cancer.

Overview of Childhood Pancreatic Tumors

T. Pysher, S. Donaldson, P. Schein, 1982 .

Phase II studies of methyl glyoxal bis‐guanylhydrazone (NSC 32946) in carcinoma of the colon and lung

P. Woolley, P. Schein, E. Mitchell, 1982, Cancer.

Combination chemotherapy for locally advanced pancreatic cancer: equivalence to external beam irradiation and implication for future management.

D. Stablein, P. Woolley, P. Schein, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1-(2-CHLOROETHYL)-3-(4-METHYL CYCL0HEXYL)-1-

V. Devita, P. Schein, B. Chabner, 1972 .

Pharmacology of Nitrosourea Anticancer Agents

P. Schein, Ann L. Wang, 1984 .

Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer

P. LoRusso, P. Schein, L. Baker, 2004, Cancer Chemotherapy and Pharmacology.

Phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in advanced colorectal cancer.

P. Woolley, D. Haller, P. Schein, 1978, Cancer treatment reports.

Mitomycin C: Experience in the United States, with emphasis on gastric cancer

P. Schein, J. Macdonald, D. Hoth, 1978, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Mitomycin C: experience in the United States, with emphasis on gastric cancer.

P. Woolley, P. Schein, J. Macdonald, 1978, Cancer chemotherapy and pharmacology.

Chapter 31 – STREPTOZOTOCIN

P. Schein, P. Byrne, 1981 .

Management of Hepatic Metastases: A General Overview

P. Schein, 1984 .

Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.

V. Devita, P. Bunn, P. Banks, 1976, Blood.

Medical Oncology: Basic Principles and Clinical Management of Cancer

P. Schein, P. Calabresi, S. Rosenberg, 1993 .

Comparison of the experimental antitumor activities of three nitrosourea derivatives chlorozotocin, RFCNU and CNCC encapsulated in liposomes with those in the free state.

P. Schein, P. Bothorel, G. Mathé, 1985, Oncology.